From Population to Precision
Super Session 5
Tackling global health challenges requires that we move from ‘reactive’ to ‘proactive’ care, and that we personalize our approach. The practice of evidence-based medicine and the continued identification of new biomarkers are vital steps in improving disease diagnosis, improving the safety and efficacy of existing medicines, and in developing new medicines and targeted therapies. In this session, we discuss the needs and challenges from both industry and financial viewpoints.
Dr. Jutta Heix - Head of International Affairs, Oslo Cancer Cluster - Super Session Chair Ms. Karin Conde-Knape - CVP Global Diabetes, Cardio-Renal and Global Drug Discovery, Novo Nordisk Ms. Carolina Haefliger - VP, Head Centre for Genomics Research, AstraZeneca Dr. Patrick Sobocki - Investment Manager, Industrifonden Mr. Karl Bergman - CEO, Elypta Dr. Gupta Udatha - Project Coordinator, DIGI-B-CUBE Dr. Falk Ehmann (TBC) - Chair Innovation Task Force, European Medicines Agency